Chemotherapy and radiotherapy: Cryptic anticancer vaccines

被引：154

作者：

Ma, Yuting ^{[2
,3
]}

Kepp, Oliver ^{[3
]}

Ghiringhelli, Francois ^{[2
,3
,4
,5
]}

Apetoh, Lionel ^{[2
,3
]}

Aymerica, Laetitia ^{[2
,3
]}

Locher, Clara ^{[2
,3
]}

Tesniere, Antoine ^{[3
]}

Martins, Isabelle ^{[3
]}

Ly, Andre ^{[2
,3
]}

Haynes, Nicole M. ^{[6
]}

Smyth, Mark J. ^{[6
]}

Kroemer, Guido ^{[1
,3
]}

Zitvogel, Laurence ^{[2
,3
]}

机构：

[1] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France

[2] INSERM, U805, F-94805 Villejuif, France

[3] Univ Paris 11, F-94805 Villejuif, France

[4] INSERM, CRI 866, AVENIR Team, F-21000 Dijon, France

[5] Ctr Georges Francois Leclerc, F-21000 Dijon, France

[6] Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic 3002, Australia

来源：

SEMINARS IN IMMUNOLOGY | 2010年 / 22卷 / 03期

基金：

英国医学研究理事会;

关键词：

Chemotherapy; Cancer; Inflammasome; Interleukin-1; beta; Interferon-gamma; COLONY-STIMULATING FACTOR; MEDIATED TUMOR DESTRUCTION; LOW-DOSE CYCLOPHOSPHAMIDE; ACUTE MYELOID-LEUKEMIA; AUGMENTS ANTITUMOR IMMUNITY; AUTOLOGOUS MELANOMA-CELLS; HEAT-SHOCK PROTEINS; REGULATORY T-CELLS; DENDRITIC CELLS; APOPTOTIC CELLS;

D O I：

10.1016/j.smim.2010.03.001

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

An attractive, yet hitherto unproven concept predicts that the promotion of tumor regression should elicit the host's immune response against residual tumor cells to achieve an optimal therapeutic effect. In a way, chemo- or radiotherapy must trigger "danger signals" emitted from immunogenic cell death and hence elicit "danger associated molecular patterns" to stimulate powerful anticancer immune responses. Here, based on the recent experimental and clinical evidence, we will discuss the molecular identity of the multiple checkpoints that dictate the success of "immunogenic chemotherapy" at the levels of the drug, of the tumor cell and of the host immune system. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：113 / 124

页数：12

共 123 条

[71] Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor-Bearing Patients [J].

Menard, Cedric ;

Blay, Jean-Yves ;

Borg, Christophe ;

Michiels, Stefan ;

Ghiringhelli, Francois ;

Robert, Caroline ;

Nonn, Celine ;

Chaput, Nathalie ;

Taieb, Julien ;

Delahaye, Nicolas F. ;

Flament, Caroline ;

Emile, Jean-Francois ;

Le Cesne, Axel ;

Zitvogel, Laurence .

CANCER RESEARCH, 2009, 69 (08) :3563-3569

[72] CD39 is the dominant Langerhans cell associated ecto-NTPDase:: Modulatory roles in inflammation and immune responsiveness [J].

Mizumoto, N ;

Kumamoto, T ;

Robson, SC ;

Sévigny, J ;

Matsue, H ;

Enjyoji, K ;

Takashima, A .

NATURE MEDICINE, 2002, 8 (04) :358-365

[73] Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients [J].

Nistico, Paola ;

Capone, Imerio ;

Palermo, Belinda ;

Del Bello, Duilia ;

Ferraresi, Virginia ;

Moschella, Federica ;

Arico, Eleonora ;

Valentini, Mara ;

Bracci, Laura ;

Cognetti, Francesco ;

Ciccarese, Mariangela ;

Vercillo, Giuseppe ;

Roselli, Mario ;

Fossile, Emanuela ;

Tosti, Maria Elena ;

Wang, Ena ;

Marincola, Francesco ;

Imberti, Luisa ;

Catricala, Caterina ;

Natali, Pier Giorgio ;

Belardeli, Filippo ;

Proietti, Enrico .

INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (01) :130-139

[74] Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer [J].

Nomi, Takeo ;

Sho, Masayuki ;

Akahori, Takahiro ;

Hamada, Kaoru ;

Kubo, Atsushi ;

Kanehiro, Hiromichi ;

Nakamura, Shinji ;

Enomoto, Koji ;

Yagita, Hideo ;

Azuma, Miyuki ;

Nakajima, Yoshiyuki .

CLINICAL CANCER RESEARCH, 2007, 13 (07) :2151-2157

[75] Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells [J].

Nowak, AK ;

Lake, RA ;

Marzo, AL ;

Scott, B ;

Heath, WR ;

Collins, EJ ;

Frelinger, JA ;

Robinson, BWS .

JOURNAL OF IMMUNOLOGY, 2003, 170 (10) :4905-4913

[76]

Nowak AK, 2003, CANCER RES, V63, P4490

[77] Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis [J].

Obeid, M. ;

Panaretakis, T. ;

Joza, N. ;

Tufi, R. ;

Tesniere, A. ;

van Endert, P. ;

Zitvogel, L. ;

Kroemer, G. .

CELL DEATH AND DIFFERENTIATION, 2007, 14 (10) :1848-1850

[78] Leveraging the immune system during chemotherapy: Moving calreticulin to the cell surface converts apoptotic death from "Silent" to immunogenic [J].

Obeid, Michel ;

Panaretakis, Theocharis ;

Tesniere, Antoine ;

Joza, Nick ;

Tufi, Roberta ;

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Zitvogel, Laurence ;

Kroemer, Guido .

CANCER RESEARCH, 2007, 67 (17) :7941-7944

[79] Calreticulin exposure dictates the immunogenicity of cancer cell death [J].

Obeid, Michel ;

Tesniere, Antoine ;

Ghiringhelli, Francois ;

Fimia, Gian Maria ;

Apetoh, Lionel ;

Perfettini, Jean-Luc ;

Castedo, Maria ;

Mignot, Gregoire ;

Panaretakis, Theoharis ;

Casares, Noelia ;

Metivier, Didier ;

Larochette, Nathanael ;

van Endert, Peter ;

Ciccosanti, Fabiola ;

Piacentini, Mauro ;

Zitvogel, Laurence ;

Kroemer, Guido .

NATURE MEDICINE, 2007, 13 (01) :54-61

[80] The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies [J].

Ozao-Choy, Junko ;

Ma, Ge ;

Kao, Johnny ;

Wang, George X. ;

Meseck, Marcia ;

Sung, Max ;

Schwartz, Myron ;

Divino, Celia M. ;

Pan, Ping-Ying ;

Chen, Shu-Hsia .

CANCER RESEARCH, 2009, 69 (06) :2514-2522

← 3 4 5 6 7 8 9 10 11 12 →